Natalia Khuri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Natalia Khuri has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Kathleen M. Giacomini
Department of Bioengineering and Therapeutic Sciences University of California San Francisco California USA
4 shared publications - Jason M. Grayson
Department of Microbiology and Immunology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America
3 shared publications - Konghao Zhao
Department of Computer Science, Wake Forest University, Winston Salem, North Carolina, USA
3 shared publications - Andrej Sali
Department of Bioengineering and Therapeutic Sciences, Department of Pharmaceutical Chemistry, Quantitative Biosciences Institute, University of California, San Francisco, San Francisco, USA
2 shared publications Eleftheria Tsakalozou
Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993
2 shared publicationsHuan-Chieh Chien
Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158
2 shared publications
Latest Publications
- Open Access
- 30 June 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-6
Multi-Objective Evolutionary Optimization for the Discovery of Structurally Diverse and Active Compounds
- 30 June 2026
- Published by Association for Computing Machinery (ACM)
- p. 1-6
Open AccessMulti-Objective Evolutionary Optimization for the Discovery of Structurally Diverse and Active Compounds
- 1 March 2025
- Published by IATED Academy in INTED Proceedings
- Vol. 1, 6206-6213
TEACH OR REACH: EMPOWERING THE NEXT GENERATION OF STUDENTS THROUGH TEXT ANALYSIS
- 1 March 2025
- Published by IATED Academy in INTED Proceedings
- Vol. 1, 6206-6213
TEACH OR REACH: EMPOWERING THE NEXT GENERATION OF STUDENTS THROUGH TEXT ANALYSIS
- 1 March 2025
- Published by IATED Academy in INTED Proceedings
- Vol. 1, 6196-6205
THE EVOLUTION OF COMPUTER SCIENCE EDUCATION RESEARCH: TRENDS, TOPICS, AND GAPS
- 1 March 2025
- Published by IATED Academy in INTED Proceedings
- Vol. 1, 6196-6205
THE EVOLUTION OF COMPUTER SCIENCE EDUCATION RESEARCH: TRENDS, TOPICS, AND GAPS
- 7 October 2024
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 213 (10) , 1441-1451
High-dimensional Immune Profiles and Machine Learning May Predict Acute Myeloid Leukemia Relapse Early following Transplant
Identification of early immune signatures associated with acute myeloid leukemia (AML) relapse following hematopoietic stem cell transplant (HSCT) is critical for patient outcomes. We analyzed PBMCs from 58 patients with AML undergoing HSCT, focusing on T cell subsets and functional profiles. High-dimensional flow cytometry coupled with Uniform Manifold Approximation and Projection dimensionality reduction and PhenoGraph clustering revealed distinct changes in CD4+ and CD8+ T cell populations in 16 patients who relapsed within 1 y of HSCT. We observed increased IL-2, IL-10, and IL-17–producing CD4+ T cells, alongside decreased CD8+ T cell function early in relapsing patients. Notably, relapsing patients exhibited increased TCF-1intermediate cells, which lacked granzyme B or IFN-γ production in the CD4+ T cell compartment. We then developed a supervised machine learning algorithm that predicted AML relapse with 90% accuracy within 30 d after HSCT using high-throughput assays. The algorithm leverages condensed immune phenotypic data, alongside the ADASYN algorithm, for data balancing and 100 rounds of XGBoost supervised learning. This approach holds potential for detecting relapse-associated immune signatures months before clinical manifestation. Our findings demonstrate a distinct immunological signature potentially capable of predicting AML relapse as early as 30 d after HSCT.
- 7 October 2024
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 213 (10) , 1441-1451
High-dimensional Immune Profiles and Machine Learning May Predict Acute Myeloid Leukemia Relapse Early following Transplant
Identification of early immune signatures associated with acute myeloid leukemia (AML) relapse following hematopoietic stem cell transplant (HSCT) is critical for patient outcomes. We analyzed PBMCs from 58 patients with AML undergoing HSCT, focusing on T cell subsets and functional profiles. High-dimensional flow cytometry coupled with Uniform Manifold Approximation and Projection dimensionality reduction and PhenoGraph clustering revealed distinct changes in CD4+ and CD8+ T cell populations in 16 patients who relapsed within 1 y of HSCT. We observed increased IL-2, IL-10, and IL-17–producing CD4+ T cells, alongside decreased CD8+ T cell function early in relapsing patients. Notably, relapsing patients exhibited increased TCF-1intermediate cells, which lacked granzyme B or IFN-γ production in the CD4+ T cell compartment. We then developed a supervised machine learning algorithm that predicted AML relapse with 90% accuracy within 30 d after HSCT using high-throughput assays. The algorithm leverages condensed immune phenotypic data, alongside the ADASYN algorithm, for data balancing and 100 rounds of XGBoost supervised learning. This approach holds potential for detecting relapse-associated immune signatures months before clinical manifestation. Our findings demonstrate a distinct immunological signature potentially capable of predicting AML relapse as early as 30 d after HSCT.
- Open Access
- 3 September 2023
- Published by Association for Computing Machinery (ACM)
- p. 1-10
An Ensemble Machine Learning Approach for Benchmarking and Selection of scRNA-seq Integration Methods
- 3 September 2023
- Published by Association for Computing Machinery (ACM)
- p. 1-10
Open AccessAn Ensemble Machine Learning Approach for Benchmarking and Selection of scRNA-seq Integration Methods
- Open Access
- 20 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (2) , 183
Multi-Objective Genetic Algorithm for Cluster Analysis of Single-Cell Transcriptomes
Cells are the basic building blocks of human organisms, and the identification of their types and states in transcriptomic data is an important and challenging task. Many of the existing approaches to cell-type prediction are based on clustering methods that optimize only one criterion. In this paper, a multi-objective Genetic Algorithm for cluster analysis is proposed, implemented, and systematically validated on 48 experimental and 60 synthetic datasets. The results demonstrate that the performance and the accuracy of the proposed algorithm are reproducible, stable, and better than those of single-objective clustering methods. Computational run times of multi-objective clustering of large datasets were studied and used in supervised machine learning to accurately predict the execution times of clustering of new single-cell transcriptomes.
- 20 January 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (2) , 183
Open AccessMulti-Objective Genetic Algorithm for Cluster Analysis of Single-Cell Transcriptomes
Cells are the basic building blocks of human organisms, and the identification of their types and states in transcriptomic data is an important and challenging task. Many of the existing approaches to cell-type prediction are based on clustering methods that optimize only one criterion. In this paper, a multi-objective Genetic Algorithm for cluster analysis is proposed, implemented, and systematically validated on 48 experimental and 60 synthetic datasets. The results demonstrate that the performance and the accuracy of the proposed algorithm are reproducible, stable, and better than those of single-objective clustering methods. Computational run times of multi-objective clustering of large datasets were studied and used in supervised machine learning to accurately predict the execution times of clustering of new single-cell transcriptomes.
- 1 March 2021
- Published by Springer Nature
- p. 657-670
Predicting Targets for Genome Editing with Long Short Term Memory Networks
- 1 March 2021
- Published by Springer Nature
- p. 657-670
Predicting Targets for Genome Editing with Long Short Term Memory Networks
- 22 June 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (27) , 16009-16018
Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives
Significance: Food and drug products are supplemented with small molecules called excipients that are assumed to be inert. In this study, we screened a collection of common oral excipients and identified 24 that inhibit intestinal drug transport, including the common excipient FD&C Red No. 40, which decreased drug absorption in mice. Excipient inhibitors were enriched for azo dyes, which human gut bacteria could metabolize, producing metabolites that no longer inhibit intestinal drug transporter activity. This work demonstrates the unintended consequences of oral excipients and a beneficial role for the gut microbiome in limiting these unfavorable effects.
- 22 June 2020
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 117 (27) , 16009-16018
Bacterial metabolism rescues the inhibition of intestinal drug absorption by food and drug additives
Significance: Food and drug products are supplemented with small molecules called excipients that are assumed to be inert. In this study, we screened a collection of common oral excipients and identified 24 that inhibit intestinal drug transport, including the common excipient FD&C Red No. 40, which decreased drug absorption in mice. Excipient inhibitors were enriched for azo dyes, which human gut bacteria could metabolize, producing metabolites that no longer inhibit intestinal drug transporter activity. This work demonstrates the unintended consequences of oral excipients and a beneficial role for the gut microbiome in limiting these unfavorable effects.
- 28 January 2020
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (3) , 748-756
Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP
Mechanistic-understanding-based selection of excipients may improve formulation development strategies for generic drug products and potentially accelerate their approval. Our study aimed at investigating the effects of molecular excipients present in orally administered FDA-approved drug products on the intestinal efflux transporter, BCRP (ABCG2), which plays a critical role in drug absorption with potential implications on drug safety and efficacy. We determined the interactions of 136 oral molecular excipients with BCRP in isolated membrane vesicles and identified 26 excipients as BCRP inhibitors with IC50 values less than 5 μM using 3H-cholecystokinin octapeptide (3H-CCK8). These BCRP inhibitors belonged to three functional categories of excipients: dyes, surfactants, and flavoring agents. Compared with noninhibitors, BCRP inhibitors had significantly higher molecular weights and SLogP values. The inhibitory effects of excipients identified in membrane vesicles were also evaluated in BCRP-overexpressing HEK293 cells at similar concentrations. Only 1 of the 26 inhibitors of BCRP identified in vesicles inhibited BCRP-mediated 3H-oxypurinol uptake by more than 50%, consistent with the notion that BCRP inhibition depends on transmembrane or intracellular availability of the inhibitors. Collectively, the results of this study provide new information on excipient selection during the development of drug products with active pharmaceutical ingredients that are BCRP substrates.
- 28 January 2020
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 17 (3) , 748-756
Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP
Mechanistic-understanding-based selection of excipients may improve formulation development strategies for generic drug products and potentially accelerate their approval. Our study aimed at investigating the effects of molecular excipients present in orally administered FDA-approved drug products on the intestinal efflux transporter, BCRP (ABCG2), which plays a critical role in drug absorption with potential implications on drug safety and efficacy. We determined the interactions of 136 oral molecular excipients with BCRP in isolated membrane vesicles and identified 26 excipients as BCRP inhibitors with IC50 values less than 5 μM using 3H-cholecystokinin octapeptide (3H-CCK8). These BCRP inhibitors belonged to three functional categories of excipients: dyes, surfactants, and flavoring agents. Compared with noninhibitors, BCRP inhibitors had significantly higher molecular weights and SLogP values. The inhibitory effects of excipients identified in membrane vesicles were also evaluated in BCRP-overexpressing HEK293 cells at similar concentrations. Only 1 of the 26 inhibitors of BCRP identified in vesicles inhibited BCRP-mediated 3H-oxypurinol uptake by more than 50%, consistent with the notion that BCRP inhibition depends on transmembrane or intracellular availability of the inhibitors. Collectively, the results of this study provide new information on excipient selection during the development of drug products with active pharmaceutical ingredients that are BCRP substrates.
- 1 December 2019
- Published by Elsevier in Value in Health Regional Issues
- Vol. 20, 191-195
Challenges in the Regulation of High-Cost Treatments: An Overview From Brazil
- 1 December 2019
- Published by Elsevier in Value in Health Regional Issues
- Vol. 20, 191-195
Challenges in the Regulation of High-Cost Treatments: An Overview From Brazil